Absci Corporation is a biotechnology company headquartered in Vancouver, Canada, with additional offices and laboratories in Seattle, Washington. Founded in 2011 by Dr. Sean McClain, Absci aims to revolutionize drug discovery and development through its integrated AI-driven platform.

The company specializes in AI-driven drug discovery and development. Its platform integrates synthetic biology, high-throughput screening, and machine learning algorithms to accelerate the production and optimization of biopharmaceuticals. AbSci's technology aims to enhance protein expression and solubility, making it easier to produce challenging proteins at scale. The company also offers contract research services to pharmaceutical and biotech firms. With partnerships with major players like Merck and Roche, AbSci continues to advance its platform to revolutionize the biopharmaceutical industry

The company's technology platform, named "Solubilization and Expression," or "AbSci," combinessyn thetic biology, high-throughput screening, and machine learning algorithms to accelerate the drug discovery process. AbSci's platform enables the rapid identification, optimization, and production of biopharmaceuticals, including antibodies, enzymes, and other protein-based therapeutics.

One of the key innovations of AbSci's platform is its ability to enhance the expression and solubility of proteins, which are often challenging to produce at scale. By leveraging AI and predictive modeling, Ab Scican predict protein behavior and optimize production processes, leading to improved yields and cost savings in biopharmaceutical manufacturing.

In addition to its drug discovery capabilities, AbSci offers contract research services to pharmaceutical andbiotechnology companies, providing access to its platform for protein engineering, optimization, and production.

Since its founding, AbSci has received significant attention and investment from both private and public sources. The company has formed partnerships with pharmaceutical giants like Merck and Roche, further validating the potential of its technology in the biopharmaceutical industry.

AbScicontinues to advance its platform and expand its partnerships in pursuit of its mission to accelerate drug discovery and enable the development of next-generation biopharmaceuticals. For the most up-to-date information on AbSci Corporation, I recommend consulting recent news articles and company announcements.